BCL9L (B Cell CLL/Lymphoma 9-like Protein, B Cell Lymphoma 9-like Protein, BCL9-like Protein, Protein BCL9-2, DLNB11)

Antibodies / Antibodies-Transcription Factors

-20°C

Supplied as a liquid in PBS, 0.02% sodium azide.

Synthetic peptide corresponding to 20aa from near the N-terminus of human Bcl9L.

Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with b-catenin, a target of the Wnt signaling pathway, and is required for enhanced ?-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating b-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.

Applications:
Suitable for use in ELISA, Western Blot and Immunocytochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 1ug/ml
Immunocytochemistry: 10ug/ml
Optimal dilutions to be determined by the researcher.

Positive Control:
HeLa Cell Lysate

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.